Esophagitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 9: Line 9:
==Medical Therapy==
==Medical Therapy==
Treatment of esophagitis depends on the underlying cause:
Treatment of esophagitis depends on the underlying cause:
*''[[Reflux esophagitis]]'': Acid suppression using proton-pump inhibitors
*''[[Reflux esophagitis|'''Reflux esophagitis''']]'': Acid suppression using proton-pump inhibitors
===Lifestyle Modifications===
===Lifestyle Modifications===
* The following measures are recommended as the first line to treat GERD:<ref name="pmid17573791">{{cite journal |author=Piesman M, Hwang I, Maydonovitch C, Wong RK |title=Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? |journal=Am. J. Gastroenterol. |volume=102 |issue=10 |pages=2128–34 |year=2007 |pmid=17573791 |doi=10.1111/j.1572-0241.2007.01348.x}}</ref><ref name="pmid16682569">{{cite journal |author=Kaltenbach T, Crockett S, Gerson LB |title=Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach |journal=Arch. Intern. Med. |volume=166 |issue=9 |pages=965–71 |year=2006 |pmid=16682569 |doi=10.1001/archinte.166.9.965}}</ref><ref name="pmid259568342">{{cite journal| author=Ness-Jensen E, Hveem K, El-Serag H, Lagergren J| title=Lifestyle Intervention in Gastroesophageal Reflux Disease. | journal=Clin Gastroenterol Hepatol | year= 2016 | volume= 14 | issue= 2 | pages= 175-82.e1-3 | pmid=25956834 | doi=10.1016/j.cgh.2015.04.176 | pmc=4636482 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25956834  }}</ref><ref>Khoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. ''Am J Gastroenterol'' 1999;94:2069-73. PMID 10445529.</ref>
* The following measures are recommended as the first line to treat GERD:<ref name="pmid17573791">{{cite journal |author=Piesman M, Hwang I, Maydonovitch C, Wong RK |title=Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? |journal=Am. J. Gastroenterol. |volume=102 |issue=10 |pages=2128–34 |year=2007 |pmid=17573791 |doi=10.1111/j.1572-0241.2007.01348.x}}</ref><ref name="pmid16682569">{{cite journal |author=Kaltenbach T, Crockett S, Gerson LB |title=Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach |journal=Arch. Intern. Med. |volume=166 |issue=9 |pages=965–71 |year=2006 |pmid=16682569 |doi=10.1001/archinte.166.9.965}}</ref><ref name="pmid259568342">{{cite journal| author=Ness-Jensen E, Hveem K, El-Serag H, Lagergren J| title=Lifestyle Intervention in Gastroesophageal Reflux Disease. | journal=Clin Gastroenterol Hepatol | year= 2016 | volume= 14 | issue= 2 | pages= 175-82.e1-3 | pmid=25956834 | doi=10.1016/j.cgh.2015.04.176 | pmc=4636482 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25956834  }}</ref><ref>Khoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. ''Am J Gastroenterol'' 1999;94:2069-73. PMID 10445529.</ref>

Revision as of 19:47, 28 December 2017

Esophagitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Esophagitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophagitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophagitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophagitis medical therapy

CDC on Esophagitis medical therapy

Esophagitis medical therapy in the news

Blogs on Esophagitis medical therapy

Directions to Hospitals Treating Esophagitis

Risk calculators and risk factors for Esophagitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The mainstay of therapy for reflux esophagitis is acid suppression therapy. Patients with infectious esophagitis are treated with antimicrobial therapy, whereas patients with eosinophilic esophagitis are treated with corticosteroids. Supportive therapy for esophagitis includes proton pump inhibitors, topical pain medications (gargled or swallowed), smoking and alcohol cessation, and endoscopy to remove any lodged pill fragments.

Medical Therapy

Treatment of esophagitis depends on the underlying cause:

Lifestyle Modifications

  • The following measures are recommended as the first line to treat GERD:[1][2][3][4]
    • Weight loss
    • Elevating head of the bed
    • No eating two hours before going sleep
  • Avoidance of the following foods and lifestyles is recommended in treatment of GERD:

Medical therapy

  • The medical therapy is indicated for the patients who have persistent GERD regardless the lifystyle and food modifications.[5][6]
  • The following medical therapies are strongly recommended by the American College of Gastroenterology:
  • Infectious esophagitis: Antibiotics, antifungals, or antivirals depending on organism (see regimens below)
  • Eosinophilic esophagitis: Topical/systemic corticosteroids (see below)[7]
  • Pill esophagitis: Stop offending drug[8]
  • Radiation esophagitis: Sucralfate, promotility agents, and viscous lidocaine[9]

Supportive care measures include:

  • Acid suppression using proton-pump inhibitors (recommended in all patients)
  • Topical pain medications (gargled or swallowed)
  • Decreasing or limiting oral intake, total parenteral nutrition (TPN) may be required for advanced cases to allow the esophagus to heal
  • Smoking/Alcohol cessation
  • Endoscopy to remove any lodged pill fragments

Antimicrobial Regimens

  • 1. Candida esophagitis[10]
  • Preferred regimen: Fluconazole 100 mg PO qd for 14–21 days OR Itraconazole solution 200 mg PO qd for 14–21 days
  • Alternative regimen (1): Itraconazole tablets 200 mg PO qd for 14–21 days
  • Alternative regimen (2): Amphotericin B 0.3–0.7 mg/kg/d IV q24h
  • Amphotericin B is reserved for patients who have failed therapy with both fluconazole and itraconazole.
  • 2. Herpes simplex virus (HSV) esophagitis[11]
  • Preferred regimen (1): Acyclovir 5 mg/kg IV q8h for 7–14 days
  • Preferred regimen (2): Acyclovir 400 mg 5 times daily PO for 14–21 days
  • Preferred regimen (3): Valacyclovir 1 g PO tid for 14–21 days ± maintenance suppressive therapy may be necessary in AIDS
  • Alternative regimen (1): Famciclovir 500 mg bid PO for 14–21 days
  • Alternative regimen (2): Foscarnet 90 mg/kg q12h IV for 7–14 days
  • 3. Cytomegalovirus (CMV) esophagitis[12]

Duration of therapy: 21–42 days or until signs and symptoms have resolved

  • Preferred Regimen (1): Ganciclovir 5 mg/kg IV q12h, may switch to valganciclovir 900 mg PO q12h once the patient can absorb and tolerate PO therapy.
  • Alternate Regimen (1): Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h for patients with treatment limiting toxicities to ganciclovir or with ganciclovir resistance OR
  • Alternate Regimen (2): Oral valganciclovir may be used if symptoms are not severe enough to interfere with oral absorption OR
  • Alternate Regimen (3): For mild cases: If ART can be initiated or optimized without delay, withholding CMV therapy may be considered.
    • Note (1): Maintenance therapy is usually not necessary, but should be considered after relapses.

Corticosteroids

  • Corticosteroids are recommended in eosinophilic esophagitis.
  • First-line regimens include:
  • Fluticasone 88–440 mcg PO qd for children, 880–1760 mcg PO qd for adults
OR
  • Budesonide 1 mg PO qd for children, 2 mg PO qd for adults
  • Patients without symptomatic and histologic improvement after topical steroids may benefit from a longer course or higher doses of topical steroids, systemic steroids with prednisone, dietary elimination, or endoscopic dilation.[13]

References

  1. Piesman M, Hwang I, Maydonovitch C, Wong RK (2007). "Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter?". Am. J. Gastroenterol. 102 (10): 2128–34. doi:10.1111/j.1572-0241.2007.01348.x. PMID 17573791.
  2. Kaltenbach T, Crockett S, Gerson LB (2006). "Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach". Arch. Intern. Med. 166 (9): 965–71. doi:10.1001/archinte.166.9.965. PMID 16682569.
  3. Ness-Jensen E, Hveem K, El-Serag H, Lagergren J (2016). "Lifestyle Intervention in Gastroesophageal Reflux Disease". Clin Gastroenterol Hepatol. 14 (2): 175-82.e1-3. doi:10.1016/j.cgh.2015.04.176. PMC 4636482. PMID 25956834.
  4. Khoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999;94:2069-73. PMID 10445529.
  5. Tran T, Lowry A, El-Serag H (2007). "Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs". Aliment Pharmacol Ther. 25 (2): 143–53. doi:10.1111/j.1365-2036.2006.03135.x. PMID 17229239.
  6. Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S. Effects of Aluminum/Magnesium Hydroxide and Calcium Carbonate on Esophageal and Gastric pH in Subjects with Heartburn. Am J Ther 1995;2:546-552. PMID 11854825.
  7. Rothenberg ME (2009). "Biology and treatment of eosinophilic esophagitis". Gastroenterology. 137 (4): 1238–49. doi:10.1053/j.gastro.2009.07.007. PMC 4104422. PMID 19596009.
  8. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M (2009). "Drug-induced esophagitis". Dis Esophagus. 22 (8): 633–7. doi:10.1111/j.1442-2050.2009.00972.x. PMID 19392845.
  9. Berkey FJ (2010). "Managing the adverse effects of radiation therapy". Am Fam Physician. 82 (4): 381–8, 394. PMID 20704169.
  10. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  11. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  12. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  13. Dellon, Evan S.; Gonsalves, Nirmala; Hirano, Ikuo; Furuta, Glenn T.; Liacouras, Chris A.; Katzka, David A.; American College of Gastroenterology (2013-05). "ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)". The American Journal of Gastroenterology. 108 (5): 679–692, quiz 693. doi:10.1038/ajg.2013.71. ISSN 1572-0241. PMID 23567357. Check date values in: |date= (help)

Template:WS Template:WH